Pfizer PFE announced today that the European Commission has
approved expanding the use of the company's pneumococcal conjugate
vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine
[13-valent, adsorbed]), to older children and adolescents aged 6 to 17
years for active immunization for the prevention of invasive disease,
pneumonia and acute otitis media caused by vaccine-type Streptococcus
pneumoniae. Children in this age group who have not previously
received Prevenar 13 may receive a single dose of the vaccine.
“Prevenar 13 has been administered to millions of infants and young
children around the world and helps protect against the often fatal
effects of pneumococcal disease,” said Emilio Emini, Ph.D., chief
scientific officer, Vaccine Research, Pfizer. “As
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in